GlassScriptPhysician profile
Robert Rudin
NPI 1720026537
$8,065.84
in general payments reported to CMS, 2019-2025
41 companies · $675 in 2025
The $675 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $195 · 2021: $1,016 · 2022: $1,894 · 2023: $2,032 · 2024: $2,074 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,781.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,628.68 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,085.60 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $908.16 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $757.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.91 | 2020-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $276.91 | 2021-2023 | Austedo Xr, Austedo |
| Astrazeneca Pharmaceuticals LP | $274.35 | 2019-2025 | Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.20 | 2022-2024 | Xifaxan, Cycloset |
| Astellas Pharma US INC | $218.77 | 2021-2025 | Veozah |
| Merck Sharp & Dohme LLC | $184.17 | 2019-2023 | Steglatro, Steglujan, Belsomra |
| Amgen INC. | $183.97 | 2020-2025 | Repatha, Otezla, Otezla |
| Otsuka America Pharmaceutical, INC. | $179.55 | 2021-2024 | Rexulti |
| Pfizer INC. | $149.37 | 2023-2025 | |
| Abbott Laboratories | $135.10 | 2021-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $133.59 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rudin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.